None listed
Conditions
Interventions
None listed
Sponsors
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants who meet all of the following four criteria will be included in the study: 1) Diagnosed with asthma according to the criteria outlined in the GINA (Global Initiative for Asthma) 2023 report. 2) Underwent clinical evaluations for asthma, including blood tests, spirometry, impulse oscillometry, and FeNO (Fractional Exhaled Nitric Oxide) measurements. 3) Evaluated for treatment response to assess the severity of asthma. 4) Received inhaled corticosteroids for a minimum of three months as part of their asthma treatment.
Exclusion criteria
Exclusion criteria: 1) Other clinically significant pulmonary diseases besides asthma (e.g., active pulmonary infections, chronic obstructive pulmonary disease [COPD], bronchiectasis, pulmonary fibrosis, cystic fibrosis, obesity-related hypoventilation syndrome, lung cancer, alpha-1 antitrypsin deficiency, primary ciliary dyskinesia) or pulmonary diseases or systemic diseases that can cause peripheral eosinophilia (e.g., allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome). 2) Important internal medicine conditions that can affect blood tests (acute upper respiratory tract infections, cardiovascular diseases, inflammatory bowel diseases, liver diseases, kidney diseases, endocrine disorders, autoimmune diseases, acute and chronic infectious diseases, hematological disorders, malignant tumors, or significant physical injuries). 3) Cases where important medications that can affect blood tests are being taken (antidiabetic medications, lipid-lowering agents, steroids, immunosuppressive agents).
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The level of asthma control (Severity, Medication, ACT score);Lung function (FEV1, FVC, FEV1/FVC, FEF25-75, DLCO);Fractional Exhaled Nitric Oxide;Impulse oscillometry (R5, R20, X5, Fres, AX);moderate to severe acute exacerbations | — |
Primary
| Measure | Time frame |
|---|---|
| Metabolites (monosaccharides, short-chain fatty acids, amino acids);Immune cells (innate immune cells: monocyte, dendritic cell, NK cell, innate lymphoid cell (ILC); adaptive immune cells: T cell, B cell) | — |
Countries
Korea, Republic of
Contacts
Public ContactHyun Woo Lee
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Outcome results
None listed